Department of Biomedical and Biotechnological Sciences, Microbiology Section, University of Catania, Catania, Italy.
Department of Biomedical and Biotechnological Sciences, Oncologic, Clinical, and General Pathology Section, University of Catania, Catania, Italy.
Microbiologyopen. 2021 Feb;10(2):e1173. doi: 10.1002/mbo3.1173.
The healthy vaginal microbiota is dominated by Lactobacillus spp., which provide an important critical line of defense against pathogens, as well as giving beneficial effects to the host. We characterized L. gasseri 1A-TV, L. fermentum 18A-TV, and L. crispatus 35A-TV, from the vaginal microbiota of healthy premenopausal women, for their potential probiotic activities. The antimicrobial effects of the 3 strains and their combination against clinical urogenital bacteria were evaluated together with the activities of their metabolites produced by cell-free supernatants (CFSs). Their beneficial properties in terms of ability to interfere with vaginal pathogens (co-aggregation, adhesion to HeLa cells, biofilm formation) and antimicrobial activity mediated by CFSs were assessed against multidrug urogenital pathogens (S. agalactiae, E. coli, KPC-producing K. pneumoniae, S. aureus, E. faecium VRE, E. faecalis, P. aeruginosa, P. mirabilis, P. vulgaris, C. albicans, C. glabrata). The Lactobacilli tested exhibited an extraordinary ability to interfere and co-aggregate with urogenital pathogens, except for Candida spp., as well as to adhere to HeLa cells and to produce biofilm in the Lactobacillus combination. Lactobacillus CFSs and their combination revealed a strong bactericidal effect on the multidrug resistant indicator strains tested, except for E. faecium and E. faecalis. The antimicrobial activity was maintained after heat treatment but decreased after enzymatic treatment. All Lactobacilli showed lactic dehydrogenase activity and production of D- and L-lactic acid isomers on Lactobacillus CFSs, while only 1A-TV and 35A-TV released hydrogen peroxide and carried helveticin J and acidocin A bacteriocins. These results suggest that they can be employed as a new vaginal probiotic formulation and bio-therapeutic preparation against urogenital infections. Further, in vivo studies are needed to evaluate human health benefits in clinical situations.
健康的阴道微生物群主要由乳杆菌属(Lactobacillus spp.)主导,它们为宿主提供了重要的防御线,抵御病原体的侵害,并带来有益的影响。我们对从健康绝经前女性阴道微生物群中分离出的乳酸杆菌(Lactobacillus)1A-TV、18A-TV 和 35A-TV 的潜在益生菌活性进行了表征。评估了这 3 株菌及其组合对临床泌尿生殖道细菌的抗菌作用,以及它们的细胞游离上清液(CFS)产生的代谢产物的活性。评估了它们在干扰阴道病原体(共聚、黏附 HeLa 细胞、生物膜形成)和 CFS 介导的抗菌活性方面的有益特性,以对抗多药泌尿生殖道病原体(无乳链球菌、大肠杆菌、产 KPC 的肺炎克雷伯菌、金黄色葡萄球菌、屎肠球菌 VRE、粪肠球菌、铜绿假单胞菌、奇异变形杆菌、普通变形杆菌、白色念珠菌、光滑念珠菌)。测试的乳杆菌表现出与泌尿生殖道病原体异常干扰和共聚的能力,除了念珠菌属外,还表现出黏附 HeLa 细胞和在乳杆菌组合中产生生物膜的能力。乳杆菌 CFS 及其组合对测试的多药耐药指示株显示出强烈的杀菌作用,除了屎肠球菌和粪肠球菌外。抗菌活性在热处理后保持,但在酶处理后降低。所有乳杆菌在乳杆菌 CFS 上均表现出乳酸脱氢酶活性和 D-和 L-乳酸异构体的产生,而只有 1A-TV 和 35A-TV 释放过氧化氢,并携带 helveticin J 和 acidocin A 细菌素。这些结果表明,它们可被用作针对泌尿生殖道感染的新型阴道益生菌制剂和生物治疗制剂。此外,需要进行体内研究来评估临床情况下对人类健康的益处。